People suffering with chronic inflammation from periodontal disease, heart disease, and arthritis, will find help in recently-discovered compounds dubbed resolvins, according to research at the Boston University Goldman School of Dental Medicine, Boston, USA.
The data suggest the key to controlling inflammation is the resolvins, rather than the elimination of infection-causing bacteria, as previously thought. Additionally, if resolvins could be developed into a treatment, they may offer a safer option than other medications because the body produces resolvins naturally.
Researchers found resolvins triggered both a drastic reduction in inflammation and regeneration of bone and tissue destroyed by periodontitis in rabbits with the disease. The study, Resolvin E1 regulates inflammation at the cellular and tissue level and restores tissue homeostasis in vivo, by Hatice Hasturk, Alpdogan Kantarci, Emilie Goguet-Surmenian, Amanda Blackwood, Chris Andry, Charles N. Serhan, and Thomas E. Van Dyke, appears online in the November 15 issue of the Journal of Immunology (
